Dr. Kris Discusses Available Targeted Therapies

Mark G. Kris, MD
Published: Wednesday, Aug 10, 2011



Lead author Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the targeted agents that are available for some of the driver mutations examined in his multicenter study. The trial focused on identifying KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, and NRAS mutations using standard multiplexed assays and FISH for EML4-ALK rearrangements and MET amplifications.

Kris explains that erlotinib, which targets EGFR, is effective in nearly 20% of lung cancer patients. He anticipates that crizotinib will soon be approved which will be effective in approximately 7% patients. Other drugs, such as trastuzumab for HER2 positive non-small cell lung cancer, are also being developed or investigated for the remaining mutations examined in the trial.


Lead author Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the targeted agents that are available for some of the driver mutations examined in his multicenter study. The trial focused on identifying KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, and NRAS mutations using standard multiplexed assays and FISH for EML4-ALK rearrangements and MET amplifications.

Kris explains that erlotinib, which targets EGFR, is effective in nearly 20% of lung cancer patients. He anticipates that crizotinib will soon be approved which will be effective in approximately 7% patients. Other drugs, such as trastuzumab for HER2 positive non-small cell lung cancer, are also being developed or investigated for the remaining mutations examined in the trial.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x